Canaccord Genuity on Specialty Pharma: TEVA's Q1 Effect on Specialty Pharma (TEVA, WPI, PRGO & MYL)
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $37.64 +2.25%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity on Specialty Pharma: TEVA's Q1 Effect on Specialty Pharma (TEVA, WPI, PRGO & MYL)
Analyst, Randall Stanicky said, "The quarter was mixed with concerns linked to (1) weak EU result, (2) lack of guidance update and (3) a combination of the two. The bottom line is that the move on guidance shouldn’t be a surprise given the CEO change but the EU result was and is a reversal from the more stable Q4 message. . . The broader question is what the read-through from Q1 is for the group in combination with macro headlines from Europe."
TEVA (Nasdaq: TEVA) (BUY - $52 target): We still see a Copaxone win as the key driver and like the risk/reward. A Copaxone win is needed and while the magnitude of upside on a win could be trimmed if EU headwinds persist (which we have to assume), we still like the trade here. . . While we make modest downward adjustments to EPS, this remains one of our best 3- to 6-month plays for those with risk appetite relative to the binary Copaxone risk.
Watson (NYSE: WPI) (BUY - $90 target): Remains our top idea on favourable growth and geographic exposure. Watson holds the most robust 3-year EPS growth at +22% fueled by the Actavis deal, least exposure to troubled EU regions and valuation that is reasonable on absolute and relative terms at < 7x 2015E p/f EPS.
Perrigo (Nasdaq: PRGO( (BUY - $125 target) offers the most defensive growth with limited exposure to Europe. Perrigo has historically proven relatively resilient in the face of macro concerns given defensive nature (trade down effect to store brand) and limited exposure to Europe.
Mylan (NYSE: MYL) (HOLD - $24 target): Inexpensive but we need greater earnings comfort for a change in view. Mylan has become both less expensive and less well owned, creating what could be a solid set-up if we had comfort or insight into (1) 2013+ earnings outlook or (2) catalysts. We don’t.
Analyst, Randall Stanicky said, "The quarter was mixed with concerns linked to (1) weak EU result, (2) lack of guidance update and (3) a combination of the two. The bottom line is that the move on guidance shouldn’t be a surprise given the CEO change but the EU result was and is a reversal from the more stable Q4 message. . . The broader question is what the read-through from Q1 is for the group in combination with macro headlines from Europe."
TEVA (Nasdaq: TEVA) (BUY - $52 target): We still see a Copaxone win as the key driver and like the risk/reward. A Copaxone win is needed and while the magnitude of upside on a win could be trimmed if EU headwinds persist (which we have to assume), we still like the trade here. . . While we make modest downward adjustments to EPS, this remains one of our best 3- to 6-month plays for those with risk appetite relative to the binary Copaxone risk.
Watson (NYSE: WPI) (BUY - $90 target): Remains our top idea on favourable growth and geographic exposure. Watson holds the most robust 3-year EPS growth at +22% fueled by the Actavis deal, least exposure to troubled EU regions and valuation that is reasonable on absolute and relative terms at < 7x 2015E p/f EPS.
Perrigo (Nasdaq: PRGO( (BUY - $125 target) offers the most defensive growth with limited exposure to Europe. Perrigo has historically proven relatively resilient in the face of macro concerns given defensive nature (trade down effect to store brand) and limited exposure to Europe.
Mylan (NYSE: MYL) (HOLD - $24 target): Inexpensive but we need greater earnings comfort for a change in view. Mylan has become both less expensive and less well owned, creating what could be a solid set-up if we had comfort or insight into (1) 2013+ earnings outlook or (2) catalysts. We don’t.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Is the global equity rally broadening? UBS weighs in
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
